ClinicalTrials.gg

Program

sovateltide

Also written as “Sovateltide”, “SPI-1620” and “PMZ-1620 along with standard treatment”.

Its studies are mostly in Stroke · Ischemic Stroke · Brain Injuries, Traumatic · Hypoxia-Ischemia, Brain · Spinal Cord Injuries, led by 2 companies.

Furthest: phase 4, since Jul 5, 202311 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharmazz85 open or runningphase 4since Jul 5, 2023Jul 31, 2019Nov 2026phase 2 · NCT05514340
Zydus Lifesciences30 open or runningphase 2since Nov 27, 2012Jan 31, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2008First study: phase 1 study in CarcinomaNew to Zydus LifesciencesZydus Lifesciences · NCT00613691 · 36 enrolled · United States
  2. Nov 27, 2012Phase 2 study in Carcinoma, Non-Small-Cell LungZydus Lifesciences · NCT01741155 · 34 enrolled · United States
  3. Jan 14, 2013Phase 2 study in Biliary Tract NeoplasmsZydus Lifesciences · NCT01773785 · 30 enrolled · United States
  4. Jul 31, 2019Pharmazz's first study: phase 2 study in StrokeNew to PharmazzPharmazz · NCT04046484 · 40 enrolled · India
  5. Aug 5, 2019Phase 3 study in Brain IschemiaPharmazz · NCT04047563 · 158 enrolled · India
  6. Aug 8, 20192 phase 2 studiesPharmazz · NCT04052737, NCT04054414
  7. Aug 22, 2022Phase 2 study in Hypoxia-Ischemia, BrainPharmazz · NCT05514340 · 40 planned · India
  8. Jan 11, 2023Phase 3 study in Ischemic StrokePharmazz · NCT05691244 · 514 planned · United States, Australia, Germany and more
  9. Jul 5, 2023Phase 4 study in StrokePharmazz · NCT05955326 · 160 enrolled · India
  10. Sep 30, 2026Phase 3 study in Brain Injuries, TraumaticPharmazz · NCT07861126 · 214 planned

Ahead

  1. Nov 2026Primary completion: phase 2 study in Hypoxia-Ischemia, BrainPharmazz · NCT05514340
  2. Dec 18, 2026Primary completion: phase 4 study in StrokePharmazz · NCT05955326
  3. Sep 2027Primary completion: phase 3 study in Ischemic StrokePharmazz · NCT05691244
  4. Feb 2028Primary completion: phase 3 study in Brain Injuries, TraumaticPharmazz · NCT07861126

TargetBeta

EDN1 →read by rule
“Sovateltide (PMZ-1620, IRL-1620) is a highly selective ETB receptor agonist and a synthetic analog of ET-1.”study text, by rule · the study

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07861126Brain Injuries, Traumatic3Not yet recruitingPharmazzFeb 2028214
NCT05955326Stroke · India4Active, not recruitingPharmazzDec 18, 2026160
NCT05691244Ischemic Stroke · United States, Australia, Germany and more3RecruitingPharmazzSep 2027514
NCT05514340Hypoxia-Ischemia, Brain · India2RecruitingPharmazzNov 202640
NCT04054414Acute Spinal Cord Injury · India2RecruitingPharmazzJun 202640
NCT04052737Alzheimer Disease · India2CompletedPharmazzDec 20, 202280
NCT04047563Brain Ischemia · India3CompletedPharmazzFeb 10, 2022158
NCT04046484Stroke · India2CompletedPharmazzApr 12, 201940
NCT01773785Biliary Tract Neoplasms · United States2TerminatedZydus LifesciencesSep 201530
NCT01741155Carcinoma, Non-Small-Cell Lung · United States2TerminatedZydus LifesciencesJul 201534
NCT00613691Carcinoma · United States1CompletedZydus LifesciencesJan 201236

How it is read

Names in the registry

  • “Sovateltide”, 3 entries
  • “SPI-1620”, 3 entries
  • “PMZ-1620 along with standard treatment”, 2 entries
  • “PMZ-1620 (sovateltide) along with standard treatment”, 2 entries
  • “Sovateltide along with standard treatment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.